Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 1;3(6):856-857.
doi: 10.1001/jamaoncol.2017.0147.

Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer

Neeraj Agarwal  1 , Andrew W Hahn  1 , David M Gill  1 , James M Farnham  2 , Austin I Poole  1 , Lisa Cannon-Albright  1
Affiliations

Independent Validation of Effect of HSD3B1 Genotype on Response to Androgen-Deprivation Therapy in Prostate Cancer

Neeraj Agarwal et al. JAMA Oncol. .

Abstract

Using data from a prostate cancer registry, this study correlated HSD3B1 genotype with response to androgen-deprivation therapy in patients with prostate cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Agarwal has received research funding through the Huntsman Cancer Institute from Medivation, Janssen, and Bayer. No other conflicts are reported.

Figures

Figure.
Figure.. Kaplan-Meier Curve of Progression-Free Survival by Number of HSD3B1 Variants
Data adjusted for Gleason score and log prostate-specific antigen level.
See this image and copyright information in PMC

References

    1. Hearn JW, AbuAli G, Reichard CA, et al. HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol. 2016;17(10):1435-1444. - PMC - PubMed
    1. Simard J, Ricketts ML, Gingras S, Soucy P, Feltus FA, Melner MH. Molecular biology of the 3beta-hydroxysteroid dehydrogenase/delta5-delta4 isomerase gene family. Endocr Rev. 2005;26(4):525-582. - PubMed
    1. Chang KH, Li R, Kuri B, et al. A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell. 2013;154(5):1074-1084. - PMC - PubMed
    1. Scher HI, Halabi S, Tannock I, et al. ; Prostate Cancer Clinical Trials Working Group . Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008;26(7):1148-1159. doi: 10.1200/JCO.2007.12.4487 - DOI - PMC - PubMed

Publication types

Substances